<DOC>
	<DOC>NCT02836483</DOC>
	<brief_summary>A Prospective, Randomized, Open, Active-controlled, Interventional, Exploratory, Phase II Trial of LCB01-0371.</brief_summary>
	<brief_title>A Clinical Study of LCB01-0371</brief_title>
	<detailed_description>This study is designed to explore antituberculosis of LCB01-0371 through the assess of the early bactericidal activity, safety of administration.</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis, Pulmonary</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<criteria>1. Korean who After listening to understand the details about the clinical trial, decided to join in the clinical study, and written consent 2. The age of consent at the time of writing, only men and women under 50 years old over 19 years old 3. The First diagnosis of tuberculosis and have not received tuberculosis treatment for TB patients 1. Known history of Rifampicin or Isoniazid resistance, and/or confirmed resistant by Xpert MTB RIF test result 2. Serious TB for example tuberculous encephalomeningitis, It is impossible to participate in clinical trials 3. Known History of nontuberculous mycobacteria positive 4. It is impossible to participate in clinical trials except TB</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>